Jasper Therapeutics completed its acquisition of Kira Pharmaceuticals, issuing common and non-voting preferred shares that shift majority ownership to former Kira holders prior to a concurrent financing. Jasper also entered a $132 million PIPE of non-voting preferred stock, granted registration rights to investors, and established a CVR structure that could pay $30 million upon a Priority Review Voucher for briquilimab. Key insiders signed support and 180-day lock-up agreements to facilitate approvals and trading stability. Separately, Kira licensed its anti-C5a and C5aR programs to Mirador for $12 million upfront, with up to $458.5 million in milestones plus royalties.

Agreement 1: Jasper Therapeutics Acquires Kira Pharmaceuticals in Stock-for-Stock Merger

  • Agreement type: Agreement and Plan of Merger
  • Counterparty: Kira Pharmaceuticals
  • Signed / Effective: Jul 16 2026 / Jul 16 2026
  • Duration / Termination: N/A
  • Reason: Expand pipeline and scale via acquisition

Agreement 2: Jasper Raises $132 Million via PIPE of Non-Voting Preferred Stock

  • Agreement type: Securities Purchase Agreement for $132 million PIPE of non-voting preferred
  • Counterparty: Investors
  • Signed / Effective: Jul 16 2026 / Jul 20 2026
  • Duration / Termination: N/A
  • Reason: Strengthen balance sheet and fund growth

Agreement 3: Jasper Grants Registration Rights for PIPE Investors

  • Agreement type: Registration Rights Agreement for PIPE resale
  • Counterparty: Investors
  • Signed / Effective: Jul 16 2026 / Jul 16 2026
  • Duration / Termination: Until registration obligations are satisfied
  • Reason: Provide resale liquidity for PIPE investors

Agreement 4: Jasper Sets CVR Structure Tied to Potential $30 Million PRV Milestone

  • Agreement type: Contingent Value Rights Agreement for $30 million PRV milestone
  • Counterparty: Rights Agent and holders of Jasper common stock of record
  • Signed / Effective: Jul 16 2026 / Jul 16 2026
  • Duration / Termination: Until milestone payment conditions satisfied
  • Reason: Align legacy holders with briquilimab milestone

Agreement 5: Jasper Secures Voting Support for Post-Merger Stockholder Matters

  • Agreement type: Support Agreements for Company Stockholder Matters
  • Counterparty: Certain directors and officers of Jasper
  • Signed / Effective: Jul 16 2026 / Jul 16 2026
  • Duration / Termination: Until stockholder vote is completed
  • Reason: Facilitate approvals for conversion and governance items

Agreement 6: Jasper and Key Holders Enter 180-Day Lock-Up Following Kira Deal

  • Agreement type: Lock-up Agreements (180-day transfer restrictions)
  • Counterparty: Directors, officers and certain stockholders of Jasper and Kira
  • Signed / Effective: Jul 16 2026 / Jul 16 2026
  • Duration / Termination: 180 days after Closing (subject to early termination conditions)
  • Reason: Promote trading stability and alignment post-merger

Agreement 7: Jasper (via Kira) Licenses C5a/C5aR Programs to Mirador for $12 Million Upfront

  • Agreement type: Exclusive global IP license for anti-C5a and C5aR programs
  • Counterparty: Mirador Therapeutics
  • Signed / Effective: Jul 13 2026 / Jul 13 2026
  • Duration / Termination: Until expiry of last royalty term
  • Reason: Monetize non-core assets and focus portfolio

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.